Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sucralfate is a cytoprotective agent primarily used to treat and prevent gastrointestinal ulcers. Chemically, it is a basic aluminum salt of sucrose octasulfate. In the acidic environment of the stomach, it undergoes polymerization to form a viscous, paste-like substance that selectively binds to the proteins of ulcerated tissue, creating a physical barrier against gastric acid, pepsin, and bile salts. Beyond its barrier function, sucralfate stimulates the synthesis of endogenous prostaglandins, promotes angiogenesis, and binds growth factors like epidermal growth factor (EGF) to facilitate tissue repair. It is also investigated for topical applications in radiation-induced dermatitis, oral mucositis, and inflammatory bowel disease, as well as for use as a phosphate binder in patients with chronic kidney disease.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sucralfate.